Adalvo and Arphio Expand Access to Teduglutide


Adalvo, in collaboration with Arphio, is proud to introduce Teduglutide, a groundbreaking treatment addressing the urgent unmet needs of patients with Short Bowel Syndrome (SBS).

Short Bowel Syndrome is a rare disease characterized by the inability of the small intestine to absorb nutrients and fluids properly, leading to significant challenges for patients in maintaining adequate nutrition and hydration. Unfortunately, there are currently no approved treatments available for this debilitating condition apart from Teduglutide.

Teduglutide represents a first-to-file / first-to-market opportunity in the rare disease segment, offering new hope for patients affected by SBS. With no alternative pharmaceutical care indicated for SBS at the moment, the medical community and patients are eagerly anticipating the availability of this critical treatment.

The brand sold approximately $270Mn globally in 2022, having a significant growth potential with Global 3Y CAGR at +9%, according to IQVIA. 

"The unmet medical need for patients with Short Bowel Syndrome is enormous, and Teduglutide presents a unique opportunity to make a significant impact on their lives. Adalvo and Arphio are proud to offer this highly complex peptide injectable product, which holds the promise to improve the quality of life for patients living with Short Bowel Syndromes," stated Dr. Shlomo Sadoun, CEO of Arphio.

"Our partnership with Arphio to bring Teduglutide to the market underscores our dedication to transforming lives. Short Bowel Syndrome is a challenging condition, and Teduglutide offers a ray of hope to those affected. At Adalvo, we are committed to pioneering solutions that make a real difference in the lives of patients." stated Anil Okay, CEO of Adalvo.

The ongoing collaboration between Adalvo and Arphio ensures a clearly outlined intellectual property pathway, securing the delivery of this transformative treatment to those who need it most. 

As Adalvo and Arphio continue their dedicated efforts toward Teduglutide's availability, they reiterate their commitment to patients and healthcare professionals alike. Aiming to ensure that this life-changing therapy reaches all eligible patients worldwide, addressing the significant unmet need in the treatment of SBS

About Adalvo

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 100 countries and for over 110 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners.

With headquarters in Malta, the company has additional offices in more than 16 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals.

We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavors, driven by a deep-rooted passion to making a difference for partners.

The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.

About Arphio

Arphio is an orphan pharmaceutical company founded on the mission to improve patients access to vital treatments for rare diseases.

We believe that collaboration always yields the best results. That is why we are driven by the conviction that it is only by combining our expertise and global market reach with leading specialists in the development of orphan products that can we make vital treatments for rare diseases available to a broader population worldwide.

Arphio is founded by pharmaceutical professionals with expertise covering all major therapeutic areas and pharmaceutical forms. We are focused on rare disease detection, market access and the supply of orphan drugs internationally.